SABCS 2022: First-Line Ribociclib Plus Endocrine Therapy Bests Chemo for Aggressive Breast Cancer
Combo tied to longer progression-free survival, fewer adverse events in patients with advanced HR-positive/HER2-negative tumors
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.